Read by QxMD icon Read

Dengue vaccine

Jyotiranjan Bal, Nguyen Ngoc Luong, Jisang Park, Ki-Duk Song, Yong-Suk Jang, Dae-Hyuk Kim
BACKGROUND: Dengue is listed as a neglected tropical disease by the Center for Disease Control and Preservation, as there are insufficient integrated surveillance strategies, no effective treatment, and limited licensed vaccines. Consisting of four genetically distinct serotypes, dengue virus (DENV) causes serious life-threatening infections due to its complexity. Antibody-dependent enhancement by pre-existing cross-reactive as well as homotypic antibodies further worsens the clinical symptoms of dengue...
February 16, 2018: Microbial Cell Factories
Nicholas P Jewell, Suzanne Dufault, Zoe Cutcher, Cameron P Simmons, Katherine L Anders
Intervention trials of vector control methods often require community level randomization with appropriate inferential methods. For many interventions, the possibility of confounding due to the effects of health-care seeking behavior on disease ascertainment remains a concern. The test-negative design, a variant of the case-control method, was introduced to mitigate this issue in the assessment of the efficacy of influenza vaccination (measured at an individual level) on influenza infection. Here, we introduce a cluster-randomized test-negative design that includes randomization of the intervention at a group level...
February 12, 2018: Biostatistics
James Duehr, Silviana Lee, Gursewak Singh, Gregory A Foster, David Krysztof, Susan L Stramer, Maria C Bermúdez González, Eva Menichetti, Robert Geretschläger, Christian Gabriel, Viviana Simon, Jean K Lim, Florian Krammer
Recent reports in the scientific literature have suggested that anti-dengue virus (DENV) and anti-West Nile virus (WNV) immunity exacerbates Zika virus (ZIKV) pathogenesis in vitro and in vivo in mouse models. Large populations of immune individuals exist for a related flavivirus (tick-borne encephalitis virus [TBEV]), due to large-scale vaccination campaigns and endemic circulation throughout most of northern Europe and the southern Russian Federation. As a result, the question of whether anti-TBEV immunity can affect Zika virus pathogenesis is a pertinent one...
January 2018: MSphere
Enny S Paixão, Maria Gloria Teixeira, Laura C Rodrigues
The recent emergence and re-emergence of viral infections transmitted by vectors-Zika, chikungunya, dengue, Japanese encephalitis, West Nile, yellow fever and others-is a cause for international concern. Using as examples Zika, chikungunya and dengue, we summarise current knowledge on characteristics of the viruses and their transmission, clinical features, laboratory diagnosis, burden, history, possible causes of the spread and the expectation for future epidemics. Arboviruses are transmitted by mosquitoes, are of difficult diagnosis, can have surprising clinical complications and cause severe burden...
2018: BMJ Global Health
Femke W Overbosch, Janke Schinkel, Ineke G Stolte, Maria Prins, Gerard J B Sonder
BACKGROUND: Dengue is increasing rapidly in endemic regions. Data on incidence among travelers to these areas are limited. Five prospective studies have been performed thus far, mainly among short-term travelers. OBJECTIVE: To obtain the attack and incidence rate (AR, IR) of dengue virus (DENV) infection among long-term travelers and identify associated risk factors. METHODS: A prospective study was performed among long-term travelers (12-52 weeks) attending the Public Health Service in Amsterdam...
2018: PloS One
The Lancet Infectious Diseases
No abstract text is available yet for this article.
February 2018: Lancet Infectious Diseases
Arthur da Costa Rasinhas, Marcos Alexandre Nunes da Silva, Gabriela Cardoso Caldas, Fernanda Cunha Jácome, Raphael Leonardo, Flávia Barreto Dos Santos, Priscila Conrado Guerra Nunes, Ortrud Monika Barth, Debora Ferreira Barreto-Vieira
The lack of an experimental animal model for the study of dengue pathogenesis is a limiting factor for the development of vaccines and drugs. In previous studies, our group demonstrated the susceptibility of BALB/c mice to infection by dengue virus (DENV) 1 and 2, and the virus was successfully isolated in several organs. In this study, BALB/c mice were experimentally infected intravenously with DENV-4, and samples of their saliva were collected. Viral RNA extracted from the saliva samples was subjected to qRT-PCR, with a detection limit of 0...
February 5, 2018: Memórias do Instituto Oswaldo Cruz
Tesfaye Gelanew, Elizabeth Hunsperger
BACKGROUND: Dengue, caused by one of the four serologically distinct dengue viruses (DENV-1 to - 4), is a mosquito-borne disease of serious global health significance. Reliable and cost-effective diagnostic tests, along with effective vaccines and vector-control strategies, are highly required to reduce dengue morbidity and mortality. Evaluation studies revealed that many commercially available NS1 antigen (Ag) tests have limited sensitivity to DENV-4 serotype compared to the other three serotypes...
February 6, 2018: Virology Journal
José Luis Arredondo-García, Sri Rezeki Hadinegoro, Humberto Reynales, Mary Noreen Chua, Doris Maribel Rivera Medina, Tawee Chotpitayasunondh, Ngoc Huu Tran, Carmen C Deseda, Dewa Nyoman Wirawan, Margarita Cortés Supelano, Carina Frago, Edith Langevin, Diana Coronel, Thelma Laot, Ana Paula Perroud, Leilani Sanchez, Matthew Bonaparte, Kriengsak Limkittikul, Danaya Chansinghakul, Sophia Gailhardou, Fernando Noriega, T Anh Wartel, Alain Bouckenooghe, Betzana Zambrano
Objective; Our objective was to describe the risk of hospital admission for virologically-confirmed dengue (VCD) and the risk of clinically-severe hospitalised VCD occurring up to four years post-first dose (Years 1 to 4) in three randomised clinical trials comparing tetravalent dengue vaccine to placebo. Methods; The RRs (relative risks) for hospitalised VCD from first dose to Year-4 were estimated by year and age-group in individual and combined studies. Results; Overall, from Year-1 to Year-4, 233 and 228 participants had ≥1 episode of hospitalised VCD in the vaccinated (N=22,603) and placebo groups (N=11,301), respectively (RR=0...
February 2, 2018: Clinical Microbiology and Infection
Wei-Lian Tan, Yean Kee Lee, Yen Fong Ho, Rohana Yusof, Noorsaadah Abdul Rahman, Saiful Anuar Karsani
Dengue is endemic throughout tropical and subtropical regions of the world. Currently, there is no clinically approved therapeutic drug available for this acute viral infection. Although the first dengue vaccine Dengvaxia has been approved for use in certain countries, it is limited to those without a previous dengue infection while the safety and efficacy of the vaccine in those elderly and younger children still need to be identified. Therefore, it is becoming increasingly important to develop therapeutics/drugs to combat dengue virus (DENV) infection...
2018: PeerJ
Eric Abachin, Samantha Convers, Stephanie Falque, Raphaël Esson, Laurent Mallet, Nolwenn Nougarede
Polymerase chain reaction (PCR) is an important molecular biology technique for in vitro amplification of nucleic acids. Reverse transcriptase quantitative PCR (RT-qPCR) and more recently reverse transcriptase digital droplet PCR (RT-ddPCR) have been developed for the quantification of nucleic acids. We developed an RT-ddPCR assay for the quantification of attenuated dengue virus serotype 2 nucleic acid and compared it with a routine RT-qPCR assay. While the routine RT-qPCR assay targets the NS5 gene, the E gene was selected for the optimization of the RT-ddPCR assay conditions...
February 2, 2018: Biologicals: Journal of the International Association of Biological Standardization
Sae-Hae Kim, Yu Na Kim, Ju Kim, Yong-Suk Jang
Mucosal vaccination is an ideal strategy to induce protective immunity in both mucosal and parenteral areas. Successful induction of an antigen-specific immune response via mucosal administration essentially requires the effective delivery of antigen into a mucosal immune inductive site, which depends on antigen delivery into M cells. We previously reported that M cells specifically express C5aR, and antigen targeting to C5aR by using specific ligands, including Co1 peptide, promotes the antigen-specific immune response in both mucosal and systemic immune compartments...
February 1, 2018: Cellular Immunology
Gregory A Poland, Richard B Kennedy, Inna G Ovsyannikova, Ricardo Palacios, Paulo Lee Ho, Jorge Kalil
Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus...
January 25, 2018: Lancet Infectious Diseases
Peter J Hotez
Antipoverty vaccines are the vaccines targeting a group of approximately 20 neglected tropical diseases (NTDs), as currently defined by the World Health Organization (WHO). The "antipoverty" moniker refers to the fact that NTDs trap populations in poverty due to their chronic and deleterious effects on child intellect and worker productivity. Therefore, NTD vaccines can be expected to promote both global health and economic advancement. Unfortunately, antipoverty vaccine development has lagged behind vaccines for major childhood infections and pandemic threats, despite evidence for their cost-effectiveness and cost-savings...
February 2, 2018: Human Vaccines & Immunotherapeutics
Paula M Villegas, Elizabeth Ortega, Lourdes Villa-Tanaca, Blanca L Barrón, Jesus Torres-Flores
Dengue fever is one of the most common viral infections in the world. Although a vaccine against dengue virus (DENV) has been approved in several countries, this disease is still considered a public health priority worldwide. The ability of three small interfering RNAs (FG-siRNAs) targeting conserved sequences in the NS4B and NS5 regions of the DENV genome to inhibit DENV replication was tested in vitro in both Vero and C6/36 cells. The FG-siRNAs were effective against DENV-1, -3, and -4, but not DENV-2. A fourth siRNA specifically targeting the NS5 region of the DENV-2 genome (SG-siRNA) was designed and tested against two different DENV-2 strains, showing high levels of inhibition in both mammalian and insect cells...
February 1, 2018: Archives of Virology
M S Mustafa, R Ramasethu
Zika virus (ZIKV) infection has recently affected 4 million people across the globe. The World Health Organization has declared Zika a "Public Health Emergency of International Concern". The disease is caused by an arbovirus and transmitted by Aedes mosquitoes. Zika has followed a pattern already set in by Dengue and Chikungunya viruses. The virus exists in sylvatic form with spillovers to humans. The present outbreak in Brazil started in May 2015 and spread rapidly to Latin America and the Caribbean. The rapid spread is due to availability of non-immune population...
January 2018: Medical Journal, Armed Forces India
Janine R Danko, Tadeusz Kochel, Nimfa Teneza-Mora, Thomas Luke, Kanakatte Raviprakash, Peifang Sun, Monika Simmons, James Moon, Rafael De La Berrara, Luis Javier Martinez, Stephen J Thomas, Richard Kenney, Larry Smith, Kevin R Porter
We conducted an open label, dose escalation Phase 1 clinical trial of a tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin® to assess safety and immunogenicity. A total of 40 dengue- and flavivirus-naive volunteers received either low-dose (1 mg) TVDV alone (N = 10, group 1), low-dose TVDV (1 mg) formulated in Vaxfectin (N = 10, group 2), or high-dose TVDV (2 mg, group 3) formulated in Vaxfectin (N = 20). Subjects were immunized intramuscularly with three doses on a 0-, 30-, 90-day schedule and monitored...
January 22, 2018: American Journal of Tropical Medicine and Hygiene
Isabel N Kantor
Dengue (DENV), zika (ZIKV) and chikungunya (CHIKV), three arbovirosis transmitted by Aedes mosquitoes, have spread in recent decades in humid tropical and subtropical zones. Dengue is epidemic in subtropical areas of Argentina. DENV infection confers lasting immunity against the infecting serotype but increases the risk of serious disease upon reinfection by any of the other three. The recombinant tetravalent vaccine Dengvaxia® prevents severe dengue and hospitalization in seropositive subjects. In 2017, Dengvaxia was approved in Argentina, for ages 9 to 45, but is not included in the national vaccination calendar...
2018: Medicina
Jacqueline Kyungah Lim, Mabel Carabali, Jung-Seok Lee, Kang-Sung Lee, Suk Namkung, Sl-Ki Lim, Valéry Ridde, Jose Fernandes, Bertrand Lell, Sultani Hadley Matendechero, Meral Esen, Esther Andia, Noah Oyembo, Ahmed Barro, Emmanuel Bonnet, Sammy M Njenga, Selidji Todagbe Agnandji, Seydou Yaro, Neal Alexander, In-Kyu Yoon
INTRODUCTION: Dengue is an important and well-documented public health problem in the Asia-Pacific and Latin American regions. However, in Africa, information on disease burden is limited to case reports and reports of sporadic outbreaks, thus hindering the implementation of public health actions for disease control. To gather evidence on the undocumented burden of dengue in Africa, epidemiological studies with standardised methods were launched in three locations in Africa. METHODS AND ANALYSIS: In 2014-2017, the Dengue Vaccine Initiative initiated field studies at three sites in Ouagadougou, Burkina Faso; Lambaréné, Gabon and Mombasa, Kenya to obtain comparable incidence data on dengue and assess its burden through standardised hospital-based surveillance and community-based serological methods...
January 21, 2018: BMJ Open
Hussin A Rothan, Mehdi R M Bidokhti, Siddappa N Byrareddy
Dissemination of vector-borne viruses, such as Zika virus (ZIKV), in tropical and sub-tropical regions has a complicated impact on the immunopathogenesis of other endemic viruses such as dengue virus (DENV), chikungunya virus (CHIKV) and human immunodeficiency virus (HIV). The consequences of the possible co-infections with these viruses have specifically shown significant impact on the treatment and vaccination strategies. ZIKV is a mosquito-borne flavivirus from African and Asian lineages that causes neurological complications in infected humans...
January 16, 2018: Journal of Autoimmunity
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"